Log in to search using one of your social media accounts:

 

Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade
cyclophosphamide, stem cell transplant, nivolumab, ipilimumab, AML (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Bet ül Oran, Guillermo Garcia-Manero, Rima M. Saliba, Gheath Al-Atrash, Elias Jabbour, Uday Popat, Farhad Ravandi, Amin Alousi, Tapan Kadia, Marina Konopleva, Courtney Dinardo, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Richard E. Champlin, Ha Source Type: research

Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
chronic lymphocytic leukemia, FCR, immunochemotherapy, molecular predictors, precision medicine (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Riccardo Moia, Fary Diop, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscaggin, Valeria Spina, Michaela Cerri, Clara Deambrogi, Ahad Ahmed Kodipad, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Francesca Romana Mauro, Ilaria Del Giud Tags: Chronic Lymphocytic Leukemia Source Type: research

Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
CLL, lenalidomide, consolidation (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Paolo Strati, Michael J. Keating, Jan A. Burger, Susan M. O'Brien, William G. Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli Source Type: research

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p
CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Nitin Jain, Philip Thompson, Jan Burger, Gautam Borthakur, Prithviraj Bose, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Naveen Garg, Xuemei Wang, Varsha Gandhi, William Plunkett, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Hagop Kantarjian Source Type: research

Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
Treatment choice can be affected by patient comorbidities. Retrospective analysis of the phase 3 DASISION study suggested baseline comorbidities did not substantially affect 1-year safety and efficacy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio Tags: Chronic Myelogenous Leukemia Source Type: research

Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
Dasatinib is a potent tyrosine kinase inhibitor (TKI) of BCR-ABL. Approved dose in the chronic phase is 100mg daily. This is however associated with notable side effects mainly myelosuppression and pleural effusion, leading to dose reductions/interruptions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kiran Naqvi, Jorge Cortes, Jeffrey Skinner, Elias Jabbour, Naveen Pemmaraju, Gautam Borthakur, Zeev Estrov, Prithviraj Bose, Philip Thompson, Hagop Kantarjian Source Type: research

Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy
Although failure to achieve molecular response milestones on tyrosine kinase inhibitors (TKIs) therapy for chronic phase (CP) chronic myeloid leukemia (CML) means that switching to a different TKI is needed to limit the risk of progression and death, there is insufficient data to show long-term outcomes in the patients who were in a molecular failure after 24 months. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Sung-Eun Lee, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Dong-Wook Kim Source Type: research

Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation
BCR-ABL1 kinase domain mutations are closely related to tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML). Although mutation analysis has been recommended in CML patients with treatment failure, there is no standard guideline according to landmark responses at specific timepoints of European LeukemiaNet (ELN) recommendation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Hee-Je Kim, Hea-Lyun Yoo, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim Source Type: research

Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adult Patients: A Single-Center Experience
HLH is a systemic condition characterized by inflammatory storm and immune-mediated organ damage. Adult M-HLH is challenging and lethal due to under recognition and diverse presentations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Rita Assi, Prajwal Boddu, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Koichi Takahashi, Marina Konopleva, Abdallah Abou Zahr, Courtney DiNardo, Gautam Borthakur, Nitin Jain, Naveen Pemmaraju, Jing Ning, Sherry Pierce, William Wier Tags: Infection, Inflammation and Cancer Source Type: research

Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Z. Kozich, V. Martinkov, Z. Pugacheva, L. Smirnova Tags: Multiple Myeloma Source Type: research

Molecular Pathophysiology of Myeloma and Clinical Applications
Therapies targeting multiple myeloma (MM) in its bone marrow (BM) microenvironment including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), histone deacetylase (HDAC) inhibitors, and monoclonal antibodies (MoAbs), prolong survival 3 to 4 fold. Novel therapies target ubiquitin proteasome receptor upstream of the proteasome to overcome PI resistance. HDAC6 inhibitors block aggresomal protein degradation and synergize with PIs. IMiDs bind and activate cereblon ubiquitin 3 ligase in MM, with degradation of IZF1/3 and downregulation of Myc and IRF4. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kenneth Anderson Source Type: research

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
Patients with accelerated phase (AP) myelofibrosis (MF;>10% blasts in bone marrow [BM] or peripheral blood [PB]) have shorter overall survival (OS) than those in the chronic phase ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Lucia Masarova, Hagop M. Kantarjian, Srdan Verstovsek Tags: Myeloproliferative Neoplasms Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Organizing Committees
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Message from the Chairmen
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by clonal hematopoiesis leading to bone marrow dysplasia and cytopenias. Recently, significant advancements have been made in understanding the pathogenic mechanisms of this disease. In particular, how a wide array of somatic mutations can induce a common clinical phenotype has been investigated. Specifically, activation of innate immune signaling (i.e. myeloid derived suppressor cells) and the NLRP3 inflammasome in hematopoietic stem/progenitor cells play a central role in the biology of MDS, leading to pyroptotic cell death and c...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: David A. Sallman, Tiffany N. Tanaka, Alan List, Rafael Bejar Tags: SOHO State of the Art Updates and Next Questions Source Type: research

Clinical practice guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) in the Netherlands
In recent years, considerable progress has been made in treatment of patients with chronic lymphocytic leukaemia (CLL) and new potent drugs have become available.Therefore, the CLL working party of the Dutch/ Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) framework revised the Dutch guidelines based on new studies and expert opinion of members of the working group. Not only efficacy, but also quality of life and socio-economic impact were taken into account in the formulation of the recommendations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: S. Kersting, S.I.M. Neppelenbroek, H.P.J. Visser, M v Gelder, M.D. Levin, R. Mous, E.F.M. Posthuma, H.M. van der Straaten, A.P. Kater Source Type: research

Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia
Patients with CBF-AML who relapse have suboptimal outcomes. We retrospectively analyzed 92 CBF-AML patients at first relapse to identify factors associated with clinical outcome. Age, high white cell count, high bone marrow blast percentage and t(8;21) cytogenetic group were associated with worse prognosis. Our findings suggest that consideration of these factors, especially t(8;21) cytogenetics, can improve prognostic stratification of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad A. Alzubaidi, Sherry A. Pierce, Farhad Ravandi, Hagop M. Kantarjian, Gautam Borthakur Source Type: research

SOHO State of the Art Update and Next Questions: Biology and Treatment of MDS
Myelodysplastic Syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by clonal hematopoiesis leading to bone marrow dysplasia and cytopenias. Recently, significant advancements have been made in understanding the pathogenic mechanisms of this disease. In particular, how a wide array of somatic mutations can induce a common clinical phenotype has been investigated. Specifically, activation of innate immune signaling (i.e. myeloid derived suppressor cells) and the NLRP3 inflammasome in hematopoietic stem/progenitor cells play a central role in the biology of MDS leading to pyroptotic cell death and cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: David A. Sallman, Tiffany N. Tanaka, Alan List, Rafael Bejar Source Type: research

Extranodal Marginal Zone Lymphoma of the Central Nervous System
We present a review of the literature and describe its presentation, differential diagnosis, treatment options, and outcomes. Systematic search of PubMed, Medline, and Embase databases via the Ovid engine for primary articles and case reports yielded 37 unduplicated peer-reviewed articles of CNS EMZBL. We identified 69 cases in these articles and 1 unreported case at our institution, which were included for this review's analysis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A. Cherry Tags: Review Source Type: research

The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma
We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Bismarck Odei, Dustin Boothe, Jonathan Frandsen, Matthew M. Poppe, David K. Gaffney Source Type: research

Results of upfront therapy for marginal zone lymphoma
Marginal zone lymphomas (MZL) represent a group of indolent lymphomas that originates from the marginal zone of lymphoid tissue. [1-3] The World Health Organization classifies these indolent lymphomas into three distinct types based on their site of origin: extranodal mucosa-associated lymphoid tissue (MALT) MZL, nodal MZL (NMZL) and the splenic MZL (SMZL). Even though these entities share common features, they also display clinical, molecular and biological heterogeneity depending on the organ where they originate from. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Jos é L. Ortega, Fernando Cabanillas, Noridza Rivera, Maribel Tirado-Gomez, Deana Hallman, Wandaly I. Pardo, Margarita Bruno Source Type: research

Extra-Nodal Marginal Zone Lymphoma Of The Central Nervous System
We present a review of the literature and describe the presentation, differential diagnosis, treatment options and outcomes of CNS EMZBL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A. Cherry Source Type: research

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML
Salvage regimens for patients with relapsed/refractory acute myeloid leukemia (rrAML) lack comparative data for superiority. Thus, we conducted a retrospective analysis of clofarabine-based (GCLAC; filgrastim, clofarabine, cytarabine) versus cladribine-based (CLAG; filgrastim, cladribine, cytarabine) regimens in rrAML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Benyam Muluneh, Kaitlyn Buhlinger, Allison M. Deal, Joshua F. Zeidner, Matthew C. Foster, Katarzyna Joanna Jamieson, Jill Bates, Hendrik W. Van Deventer Source Type: research

Consolidative Radiotherapy After Autologous Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Patients with relapsed or refractory diffuse large B-cell lymphoma undergoing autologous bone marrow transplantation benefited from consolidative involved-field radiotherapy (IFRT). All patients who underwent consolidative IFRT had improved locoregional control. Additionally, patients with enlarged lymphadenopathy had an improved locoregional control, disease-free survival, and overall survival at the 2-year evaluation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Brendan G. Coutu, Christopher T. Wilke, Jianling Yuan, Qing Cao, Matthew R. Vernon, Chung Lee, Veronika Bachanova, Kathryn E. Dusenbery Tags: Original Study Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized as a result of its technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark Tags: Original Study Source Type: research

Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Early-stage Hodgkin lymphoma is a highly curable malignancy. However, the outcomes for elderly patients have remained suboptimal. We conducted a retrospective study using the National Cancer Database to assess the therapies used for elderly patients with early-stage Hodgkin lymphoma from 2004 to 2012. Our results showed improved survival with combined chemotherapy and radiation therapy. However, the usage of the latter remains suboptimal. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Gaurav Goyal, Edward B. Maldonado, Tiffany J. Fan, Arun Kanmanthareddy, Peter T. Silberstein, Ronald S. Go, James O. Armitage Tags: Original Study Source Type: research

Consolidative radiotherapy following autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma.
To evaluate the role of consolidative radiotherapy in patients undergoing high dose chemotherapy and autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Brendan G. Coutu, Christopher T. Wilke, Jianling Yuan, Qing Cao, Matthew R. Vernon, Chung Lee, Veronika Bachanova, Kathryn E. Dusenbery Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke included UTI, hypernatremia and acute renal failure. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Na ïve Patients
The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized due to technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark Source Type: research

Treatment Patterns and Outcomes in Early Stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Early stage Hodgkin lymphoma is a highly curable malignancy. However, outcomes for elderly patients remain suboptimal. We conducted a retrospective study using the National Cancer Database to assess therapies used among elderly patients with early stage Hodgkin lymphoma from 2004-2012. Our results show improved survival with combined chemotherapy and radiation therapy. However, the utilization of latter remains suboptimal. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Gaurav Goyal, Edward B. Maldonado, Tiffany J. Fan, Arun Kanmanthareddy, Peter T. Silberstein, Ronald S. Go, James O. Armitage Source Type: research

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematologic Malignancies
The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematologic malignancies. It is important to provide adequate treatment to both hematologic malignancies and solid tumors appropriately. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Satoshi Nishiwaki, Shingo Okuno, Kotaro Suzuki, Shingo Kurahashi, Isamu Sugiura Tags: Original Study Source Type: research

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
The combination of bortezomib, cladribine, and rituximab is novel and effective in mantle-cell and indolent non-Hodgkin lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Soham D. Puvvada, Jos é Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel O. Persky Tags: Original Study Source Type: research

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic hematopoietic cell transplant. Overall, CLAG plus IM was well tolerated, with encouraging signs of activity in patients with po...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List, Rami S. Komrokji Tags: Original Study Source Type: research

Stability of Spinal Bone Lesions in Patients With Multiple Myeloma After Radiotherapy —A Retrospective Analysis of 130 Cases
This retrospective analysis evaluated the response regarding bone density and stability of patients with osteolytic spinal bone lesions due to multiple myeloma after palliative radiotherapy. The rate of unstable lesions decreased from 51% to 24%, and the bone density showed a significant increase 6 months after radiotherapy. Palliative radiotherapy is an effective method resulting in a significant increase for local response and stability without severe RT-related toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Kristin Lang, Laila K önig, Thomas Bruckner, Robert Förster, Tanja Sprave, Ingmar Schlampp, Tilman Bostel, Stefan Welte, Nils H. Nicolay, Jürgen Debus, Harald Rief Tags: Original Study Source Type: research

Blood Transfusion Management and Transfusion-related Outcomes in Daratumumab-treated Patients With Relapsed or Refractory Multiple Myeloma
Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse events from the phase 2 SIRIUS clinical trial were analyzed and an in-depth analysis from 2 clinical study sites is reported. RBC transfusion-related adverse events, including hemolysis, were not observed among daratumumab-treated patients, confirming that transfusions may be safely administered. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Ajai Chari, Suzanne Arinsburg, Sundar Jagannath, Toshihisa Satta, Ivey Treadwell, Donna Catamero, Gillian Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan, Parul Doshi, Saad Usmani Source Type: research

A Phase II, Open-Label Study of Bortezomib (Velcade ®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas
Bortezomib, Cladribine and Rituximab (VCR) is a novel and effective combination in mantle cell and indolent non-Hodgkin ’s lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Soham D. Puvvada, Jose Guillen, Abhijeet Kumar, Lora Inclan, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel Persky Source Type: research

Stability of spinal bone lesions in patients with Multiple Myeloma after radiotherapy - a retrospective analysis of 130 cases
Objective of this retrospective analysis was the response evaluation regarding bone density and stability of patients with osteolytic spinal bone lesions due to multiple myeloma after palliative radiotherapy (RT). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Kristin Lang, Laila K önig, Thomas Bruckner, Robert Förster, Tanja Sprave, Ingmar Schlampp, Tilman Bostel, Stefan Welte, Nils H. Nicolay, Jürgen Debus, Harald Rief Source Type: research

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective switch from Second Generation Tyrosine Kinase Inhibitor to Imatinib.
The second-generation TKIs (2G-TKIs) Dasatinib (DAS) and Nilotinib (NIL) yield faster responses in newly diagnosed chronic phase (CP) CML as compared to Imatinib (IM) however, long-term safety of these agents is a growing concern. We identified 20 patients with CP CML diagnosed between 08/2013 and 10/2016 who initiated 2G-TKIs and were then switched after optimal response at 3 months to IM. Second generation TKIs initiated were DAS (n=15), NIL (n=3), both sequentially due to intolerance (n=1). One other patient initiated therapy with Ponatinib on trial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Vamsi K. Kota, Jee Hyun Kong, Martha L. Arellano, Fuad El Rassi, Manila Gaddh, Leonard T. Heffner, Elliott F. Winton, Anand P. Jillella, Morgan L. McLemore, H. Jean Khoury Source Type: research

A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in Relapsed or Refractory Acute Myeloid Leukemia
There is no standard salvage chemotherapy regimen for relapsed or refractory (RR) Acute Myeloid Leukemia (AML). Preclinical data suggested synergy in vitro between cytarabine and Imatinib Mesylate (IM) on AML cell growth inhibition. After demonstrating safety and feasibility with a phase I study, we conducted a phase 2 clinical study of Cladribine, Cytarabine, G-CSF (CLAG) regimen in combination with IM in patients with RR-AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List, Rami S. Komrokji Source Type: research

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
Existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors appropriately. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Satoshi Nishiwaki, Shingo Okuno, Kotaro Suzuki, Shingo Kurahashi, Isamu Sugiura Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Retrospective Study of Adults With Acute Lymphoid Leukemia in Mexico City: First Report of the Working Group for Acute Leukemia (GTLA)
The prognosis of adult acute lymphoblastic leukemia (ALL) is dire, with a long-term survival of 40-50%. Several studies have reported a worse prognosis in Hispanics with ALL. There are no existing large multicenter series of ALL patients in Mexico that analyze survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Erick Crespo-Solis, Karla Espinosa-Bautista, Martha Alvarado-Ibarra, Etta Rozen-Fuller, Fernando Perez-Rocha, Chantal Nava-Gomez, Maricela Ortiz-Zepeda, Jose Luis Alvarez-Vera, Christian Omar Ramos-Pe ñafiel, Luis Antonio Meillon-Garcia, Sergio Rodriguez Source Type: research

KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4
We present preliminary ZUMA-4 phase 1 results. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Daniel W. Lee, Alan Wayne, Van Huynh, Rupert Handgretinger, Rob Pieters, Gerard Michel, Andre Baruchel, Tobias Feuchtinger, Yves Bertrand, Michelle Hemiston, Patrick Brown, John Rossi, Yizhou Jiang, Lynn Navale, Shanna Stout, Jeff Aycock, Armen Mardiros, Source Type: research

Axi-cel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions
Outcomes in adult R/R ALL are poor. Promising results were observed with axi-cel (formerly KTE-C19) in B cell malignancies. Severe cytokine release syndrome (CRS) and neurologic events (NE) have been observed with anti-CD19 CAR T cell therapy in R/R ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bijal Shah, Wendy Stock, William Wierda, Max Topp, Marie Jos é Kersten, Roch Houot, Nicolas Boissel, Houston Holmes, Gary Schiller, Armen Mardiros, John Rossi, Yizhou Jiang, Tong Shen, Jeff Aycock, Shanna Stout, Jeff Wiezorek, Rajul Jain Source Type: research

Nelarabine in Adult Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma(T-ALL/T-LBL): The Mayo Clinic Experience
First line treatment strategies for adults with T-ALL/T-LBL are suboptimal, with over 50% of patients relapsing. Long term survival in the relapsed and refractory setting is ∼10%. The goal of salvage therapy is to achieve a durable response as a bridge to stem cell transplant (HCT). Nelarabine, a purine nucleoside analog, has been used for salvage therapy with reasonable success. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Theodora Anagnostou, Mark R. Litzow, Michelle A. Elliott, Aref Al-Kali, Naseema Gangat, Kristen B. McCullough, Hassan Alkhateeb, Mrinal M. Patnaik Source Type: research